Aurinia Q4 2022 Earnings Report
Key Takeaways
Aurinia Pharmaceuticals Inc. reported a total net revenue of $28.4 million for the fourth quarter of 2022, representing a 21% increase compared to the same period in 2021. The company's cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022. The company reiterated its net product revenue guidance of $120 to $140 million for fiscal year 2023.
Total net revenue for Q4 2022 was $28.4 million, a 21% increase over Q4 2021.
Net product revenue for Q4 2022 was $28.3 million.
Aurinia added 406 PSFs during the fourth quarter 2022, a 15% decrease from the fourth quarter 2021 (477).
Cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022.
Aurinia
Aurinia
Aurinia Revenue by Segment
Forward Guidance
For fiscal year 2023, the Company is reiterating its previous net product revenue guidance of $120 to $140 million from sales of LUPKYNIS. This range represents a double-digit percentage increase in net product revenue from sales of LUPKYNIS compared to fiscal year 2022.